Please assess the completion status of the following clinical trial:

Trial Title: A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of pancreatic adenocarcinoma~* Stage III or IV disease~* Age \> 17 \< 76 years~* Karnofsky Performance Status \> 50~* Measurable disease (only for phase II part)~* Adequate bone marrow (GB \> 3500/mm3, neutrophils \> 1500/mm3; platelets \> 100000/mm3; hemoglobin \> 10 g/dl), liver (total bilirubin \< 2 mg/dL; SGOT e SGPT \< 3 UNL) and kidney function (serum creatinin \< 1.5 mg/dL;)~* Written informed consent~Exclusion Criteria:~* previous chemotherapy~* concurrent treatment with other experimental drugs~* previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease at least from 5 years~* symptomatic brain metastases~* history of interstitial lung disease~* presence of serious disease which can compromise safety (cardiac failure, previous myocardial infarction within the prior 6 months, cardiac arrhythmia, history of psychiatric disabilities)~* pregnancy and lactating~* History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PAXG regimen (Type: EXPERIMENTAL): cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
- gemcitabine + nab-paclitaxel (Type: ACTIVE_COMPARATOR): gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).